Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Cited In for PubMed (Select 12464649)


Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.

Ohman AW, Hasan N, Dinulescu DM.

Front Oncol. 2014 Nov 18;4:322. doi: 10.3389/fonc.2014.00322. eCollection 2014. Review.


Preventive care and evaluation of the adolescent with a breast mass.

Jayasinghe Y.

Semin Plast Surg. 2013 Feb;27(1):13-8. doi: 10.1055/s-0033-1343990.


Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.

Friebel TM, Domchek SM, Rebbeck TR.

J Natl Cancer Inst. 2014 Jun;106(6):dju091. doi: 10.1093/jnci/dju091. Review. Erratum in: J Natl Cancer Inst. 2014 Aug;106(8):dju235 doi:10.1093/jnci/dju235.


Two decades after BRCA: setting paradigms in personalized cancer care and prevention.

Couch FJ, Nathanson KL, Offit K.

Science. 2014 Mar 28;343(6178):1466-70. doi: 10.1126/science.1251827.


BRCA and Early Events in the Development of Serous Ovarian Cancer.

George SH, Shaw P.

Front Oncol. 2014 Jan 23;4:5. doi: 10.3389/fonc.2014.00005. eCollection 2014. Review.


Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS.

Lee E, Horn-Ross PL, Rull RP, Neuhausen SL, Anton-Culver H, Ursin G, Henderson KD, Bernstein L.

Am J Epidemiol. 2013 Nov 1;178(9):1403-13. doi: 10.1093/aje/kwt154. Epub 2013 Sep 5.


Challenging and complex decisions in the management of the BRCA mutation carrier.

Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, Bakkum-Gamez JN.

J Womens Health (Larchmt). 2013 Oct;22(10):825-34. doi: 10.1089/jwh.2013.4407. Epub 2013 Aug 29. Review.


Establishing a program for individuals at high risk for breast cancer.

Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B.

J Cancer. 2013 Jul 1;4(5):433-46. doi: 10.7150/jca.6481. Print 2013.


Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.

Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP.

Cell Cycle. 2012 Nov 15;11(22):4152-66. doi: 10.4161/cc.22226. Epub 2012 Oct 9.


Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR.

J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.


Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.

Bougie O, Weberpals JI.

Int J Surg Oncol. 2011;2011:374012. doi: 10.1155/2011/374012. Epub 2011 Aug 8.


The risk of breast cancer in women with a BRCA1 mutation from North America and Poland.

Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, Stawicka M, Foulkes WD, Kilar E, Kim-Sing C, Neuhausen SL, Armel S, Gilchrist D, Sweet K, Gronwald J, Eisen A, Gorski B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2012 Jul 1;131(1):229-34. doi: 10.1002/ijc.26369. Epub 2011 Sep 22.


Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.

Pruthi S, Gostout BS, Lindor NM.

Mayo Clin Proc. 2010 Dec;85(12):1111-20. doi: 10.4065/mcp.2010.0414. Review.


Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer.

Shulman LP, Dungan JS.

Cancer Treat Res. 2010;156:69-85. doi: 10.1007/978-1-4419-6518-9_6. Review. No abstract available.


Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E, Kast WM.

PLoS One. 2010 May 12;5(5):e10471. doi: 10.1371/journal.pone.0010471.


Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.

Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F; Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM.

Breast Cancer Res Treat. 2010 Nov;124(2):441-51. doi: 10.1007/s10549-010-0842-y. Epub 2010 Mar 23.


The prevention of hereditary breast and ovarian cancer: a personal view.

Narod S.

Hered Cancer Clin Pract. 2004 Feb 15;2(1):5-10. doi: 10.1186/1897-4287-2-1-5.


Towards evidence-based management of inherited breast and breast-ovarian cancer.

Møller P.

Hered Cancer Clin Pract. 2004 Dec 15;2(1):11-6. doi: 10.1186/1897-4287-2-1-11.


Clinical, molecular and geographical features of hereditary breast/ovarian cancer in latvia.

Gardovskis A, Irmejs A, Miklasevics E, Borosenko V, Bitina M, Melbarde-Gorkusa I, Vanags A, Kurzawski G, Suchy J, Górski B, Gardovskis J.

Hered Cancer Clin Pract. 2005 Apr 15;3(2):71-6. doi: 10.1186/1897-4287-3-2-71.


Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Kurian AW, Sigal BM, Plevritis SK.

J Clin Oncol. 2010 Jan 10;28(2):222-31. doi: 10.1200/JCO.2009.22.7991. Epub 2009 Dec 7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk